Lytix Biopharma AS (LYTIX) - Total Liabilities

Latest as of December 2025: Nkr19.77 Million NOK ≈ $2.08 Million USD

Based on the latest financial reports, Lytix Biopharma AS (LYTIX) has total liabilities worth Nkr19.77 Million NOK (≈ $2.08 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Lytix Biopharma AS (LYTIX) net asset momentum to track the company's year-over-year net asset growth rate.

Lytix Biopharma AS - Total Liabilities Trend (2017–2025)

This chart illustrates how Lytix Biopharma AS's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Lytix Biopharma AS generate to measure how efficiently the company converts operating cash flow to free cash.

Lytix Biopharma AS Competitors by Total Liabilities

The table below lists competitors of Lytix Biopharma AS ranked by their total liabilities.

Company	Country	Total Liabilities
Unifi Inc NYSE:UFI	USA	$160.50 Million
MANUKA RESOURCES LTD F:6M0A	Germany	€44.13 Million
WINS Co. Ltd KQ:136540	Korea	₩23.42 Billion
Poalim Ibi TA:PIU	Israel	ILA33.81 Million
Central Plains Bancshares, Inc. Common Stock NASDAQ:CPBI	USA	$447.98 Million
Great Elm Capital Corp NASDAQ:GECC	USA	$175.29 Million
Shanghai Shibei Hi-Tech Co Ltd B SHG:900902	China	$12.13 Billion
Brand Engagement Network Inc NASDAQ:BNAI	USA	$9.03 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Lytix Biopharma AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Lytix Biopharma AS.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.28	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	0.57	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.32	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Lytix Biopharma AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Lytix Biopharma AS (2017–2025)

The table below shows the annual total liabilities of Lytix Biopharma AS from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	Nkr19.77 Million ≈ $2.08 Million	-48.83%
2024-12-31	Nkr38.64 Million ≈ $4.07 Million	+207.77%
2023-12-31	Nkr12.55 Million ≈ $1.32 Million	-25.67%
2022-12-31	Nkr16.89 Million ≈ $1.78 Million	+26.64%
2021-12-31	Nkr13.34 Million ≈ $1.40 Million	+4.79%
2020-12-31	Nkr12.73 Million ≈ $1.34 Million	+230.25%
2019-12-31	Nkr3.85 Million ≈ $405.55K	-78.41%
2018-12-31	Nkr17.85 Million ≈ $1.88 Million	-49.44%
2017-12-31	Nkr35.30 Million ≈ $3.71 Million	--

About Lytix Biopharma AS

OL:LYTIX Norway Biotechnology

Market Cap

$73.64 Million

Nkr699.79 Million NOK

Market Cap Rank

#20354 Global

#179 in Norway

Share Price

Nkr9.10

Change (1 day)

+1.34%

52-Week Range

Nkr6.90 - Nkr11.50

All Time High

Nkr18.60